Table I.

Association of AQP3 and AQP5 expression with established clinicopathological parameters in 96 patients with TNBC.

		AQP3 expression n (%)			AQP5 expression n (%)
Factor	No.	Low	High	P-value	Low	High	P-value
Age
≤50 years	51	21 (41.2)	30 (58.8)	0.734	24 (47.1)	27 (52.9)	0.172
>50 years	45	17 (37.8)	28 (62.2)		15 (33.3)	30 (66.7)
Menopausal status
Pre-menopause	58	23 (39.7)	35 (60.3)	0.986	26 (44.8)	32 (55.2)	0.300
Post-menopause	38	15 (39.5)	23 (60.5)		13 (34.2)	25 (65.8)
Surgery
Mastectomy	67	25 (37.3)	42 (62.7)	0.489	27 (40.3)	40 (59.7)	0.921
Breast conserving	29	13 (44.8)	16 (55.2)		12 (41.4)	17 (58.6)
Histological grade
I	16	5 (31.3)	11 (68.8)	0.321	7 (43.8)	9 (56.3)	0.287
II	44	21 (47.7)	23 (52.3)		21 (47.7)	23 (52.3)
III	36	12 (33.3)	24 (66.7)		11 (30.6)	25 (69.4)
Tumor size
T1	36	20 (55.6)	16 (44.4)	0.035	22 (61.1)	14 (38.9)	0.001
T2	46	15 (32.6)	31 (67.4)		16 (34.8)	30 (65.2)
T3~T4	14	3 (21.4)	11 (78.6)		1 (7.1)	13 (92.9)
Nodal status
Negative	59	28 (47.5)	31 (52.5)	0.046	30 (50.8)	29 (49.2)	0.010
Positive	37	10 (27.0)	27 (73.0)		9 (24.3)	28 (75.7)
Distant metastasis
M0	79	36 (45.6)	43 (54.4)	0.021	38 (48.1)	41 (51.9)	0.003
M1	17	2 (11.8)	15 (88.2)		1 (5.9)	16 (94.1)
Ki-67 level
Low expression	18	8 (44.4)	10 (55.6)	0.640	12 (66.7)	6 (33.3)	0.013
High expression	78	30 (38.5)	48 (61.5)		27 (34.6)	51 (65.4)

TNBC, triple-negative breast cancer; AQP, aquaporin.